Skip to main content

Table 3 Indications for WBMRI introduced during the course of MBC re-assessment which were previously assessed with CT or FDG-PET/CT

From: Does the addition of whole-body MRI to routine imaging influence real-world treatment decisions in metastatic breast cancer?

Indications for WBMRI N (%)
Clinical symptoms (e.g. bone pain, limb weakness) 20 (24.7)
Indeterminate findings on other imaging modalities 16 (19.8)
Rise in tumour markers 8 (9.9)
Bone-only disease which was difficult to assess with CT 7 (8.6)
Pseudocirrhotic liver 4 (4.9)
Deranged blood results (e.g. anaemia, pancytopaenia, hypercalcaemia) 4 (4.9)
Recommended by radiologist or at the multidisciplinary team meeting 3 (3.7)
Other (e.g. CT/FDG-PET/CT declined by patients due to radiation concerns, clinical trial entry requirements) 7 (8.6)
Combination of indications: Rise in CA 15–3 tumour marker plus: clinical symptoms 8 (9.9)
indeterminate findings on other imaging modalities 1 (1.2)
deranged blood results 2 (2.4)
recommended by radiologist 1 (1.2)